Simvastatin Coronary Atherosclerosis

Scandinavian Simvastatin Survival Study AC AT acyl CoA cholesterol acyltransferase AFCAPS/TexCAPS Air Eorce/Texas Coronary Atherosclerosis... [Pg.449]

Seljeflot I, Tonstad S, Hjermann I, Arnesen H, Reduced expression of endothelial cell markers after I year treatment with simvastatin and atorvastatin in patients with coronary heart disease, Atherosclerosis 2002 162 179-1 85,... [Pg.170]

Vittone F, Chait A, Morse JS, Fish B, Brown BG, Zhao XQ (2007) Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance a subgroup analysis of the HDL-Atherosclerosis Treatment Study (HATS). J Clin Lipidol 1 203-210... [Pg.290]

The HDL-Atherosclerosis Treatment Study (HATS) was a three-year, double-blind angiographic trial of 160 patients with coronary disease, low HDL and normal LDL. Subjects were randomized to simvastatin plus niacin or to placebo. The placebo group demonstrated an increase of 3.9% mean stenosis while the simvastatin-niacin group demonstrated 0.4% regression (P<0.001). Major cardiovascular events, including need for revascularization, were significantly decreased in the simvastatin-niacin group (P = 0.04) (Brown et al. 2001). [Pg.699]

Big Chemical Encyclopedia